Topics:

Nereus initiates phase 1b trial of NPI-2358 in NSCLC patients

Nereus initiates phase 1b trial of NPI-2358 in NSCLC patients

SAN DIEGO—Nereus Pharmaceuticals, Inc. has begun enrolling patients in an open-label phase 1b study evaluating its vascular disrupting agent NPI-2358 in combination with docetaxel (Taxotere) in patients with non-small-cell lung cancer who previously failed at least one chemotherapy regimen. NPI-2358 selectively attacks existing tumor blood vessels leading to hemorrhagic tumor necrosis without affecting normal vasculature and it has a direct apoptotic effect on tumor cells.

 
Loading comments...
Please Wait 20 seconds or click here to close